BioCancell Ltd. today announced that it has begun developing a new product, designated BC-830, for a new, non-invasive method for the follow-up of bladder cancer recurrence, based on the H19 gene as a biomarker, for which it has filed a PCT patent request.
Diagnosis and follow-up of bladder cancer currently requires one of two tests: urine cytology and cystoscopy. These tests are characterized by significant drawbacks: cytology suffers from limited sensitivity (the ability to obtain a positive result given the presence of cancer) of 45.5%, while cystoscopy is invasive, expensive and very unpleasant for the patient.
BC-830 has been designed for following up bladder cancer patients. Only BC-830-positive patients will need to undergo cystoscopy, so the use of BC-830 could replace a large proportion of existing follow-up tests, while improving diagnosis, reducing healthcare costs and improving patient quality of life.
BioCancell’s initial tests have shown that BC-830’s sensitivity reaches 95.5%, and its negative predictive value (the probability that there is no bladder cancer given a negative result) is 98.3%.
Estimates included herein are forward-looking information, based on information currently in the Company’s possession. These estimates may not be realized, entirely or in part, or may be realized in a different manner than estimated as result of various factors including: the lack of sufficient funding sources, or success in any of the phases of the trials that the Company is performing and/or planning, non-approval of patent applications, the development of competitive products, difficulty in recruiting patients for various trials, dependency on regulatory approvals and the like.
Comments are closed.